肿瘤可塑性与药物治疗抵抗

doi:10.3969/j.issn.1000-8535.2024.03.001

广州医药 ›› 2024, Vol. 55 ›› Issue (3): 213-220.DOI: 10.3969/j.issn.1000-8535.2024.03.001

• 专家述评 • 下一篇

肿瘤可塑性与药物治疗抵抗

何丹, 成炜, 刘铭

广州医科大学基础医学院（广东广州 511436)

收稿日期:2024-02-04 出版日期:2024-03-20 发布日期:2024-04-12
通讯作者: 刘铭,E-mail：liuming@gzhmu.edu.cn
作者简介:刘铭广州医科大学教授,博士生导师; 博士毕业于香港大学医学院临床肿瘤学系; 国家自然科学基金优秀青年项目获得者（2022）,广东省高等学校青年珠江学者（2018）,广东省珠江人才计划引进高层次人才（2017）,香港青年科学家奖获得者（2014）; 担任中国病理生理学会青年委员、中国药理学会青年委员、美国癌症研究学会会员、香港科学会会员; 近年来致力于借助肿瘤遗传学、分子生物学、生物信息学等研究手段,从胚胎发育角度探索肿瘤发生发展及耐药复发的分子机制; 团队围绕肿瘤可塑性及药物靶点发现展开系列研究,开发创新型抗肿瘤药物及分子诊断标志物,并积极推动其向临床转化; 近年来以通讯作者在Sci Transl Med,PNAS,Nat Commun等高影响力期刊发表多篇代表性论文; 获中国发明专利2项,美国实质审查阶段专利1项,研究成果实现对跨国公司授权转化
基金资助:
国家自然科学基金（82122048,82003773,82203380）; 广东省基础与应用基础研究基金（2023A1515011416）

Tumor Plasticity and Therapeutic Resistance

HE Dan, CHENG Wei, LIU Ming

School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,Guangdong,China

Received:2024-02-04 Online:2024-03-20 Published:2024-04-12

摘要/Abstract

摘要： 药物治疗抵抗在临床实践中成为肿瘤治疗失败的主因。最近的研究指出,肿瘤细胞的耐药性可能源于其内部高度的细胞异质性,而这种异质性的基础则是肿瘤可塑性。肿瘤细胞可塑性可能引发一系列反应,包括对治疗的耐药性发展、免疫系统逃逸以及对周围组织和血管系统的侵袭和转移等。本文简要介绍肿瘤细胞可塑性的表现形式以及其在药物治疗抵抗的非遗传适应性机制与靶向治疗新策略。

关键词: 肿瘤可塑性, 药物治疗抵抗, 肿瘤异质性, 治疗新策略

Abstract: Drug therapy resistance has emerged as a primary cause of treatment failure in cancer management．Recent research indicates that the resistance of tumor cells may stem from their high degree of intracellular heterogeneity,with the underlying basis being tumor plasticity．Tumor cell plasticity can trigger a cascade of responses,including the development of resistance to treatment,evasion of the immune system,and invasion and metastasis into surrounding tissues and the vascular system．This article provides a brief overview of the manifestations of tumor cell plasticity and its non-genetic adaptive mechanisms in drug therapy resistance,along with novel strategies for targeted treatment．

Key words: tumor plasticity, drug therapy resistance, tumor heterogeneity, novel treatment strategies

何丹, 成炜, 刘铭. 肿瘤可塑性与药物治疗抵抗[J]. 广州医药, 2024, 55(3): 213-220.

HE Dan, CHENG Wei, LIU Ming. Tumor Plasticity and Therapeutic Resistance[J]. Guangzhou Medical Journal, 2024, 55(3): 213-220.

参考文献

[1] DENTRO S C,LESHCHINER I,HAASE K,et al.Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes[J].Cell,2021,184(8):2239-2254.e39.
[2] BOUMAHDI S,de SAUVAGE F J.The great escape:tumour cell plasticity in resistance to targeted therapy[J].Nat Rev Drug Discov,2020,19(1):39-56.
[3] PÉREZ-GONZÁLEZ A,BÉVANT K,BLANPAIN C.Cancer cell plasticity during tumor progression,metastasis and response to therapy[J].Nat Cancer,2023,4(8):1063-1082.
[4] QIN S,JIANG J,LU Y,et al.Emerging role of tumor cell plasticity in modifying therapeutic response[J].Signal Transduct Target Ther,2020,5(1):228.
[5] Erin N,Grahovac J,Brozovic A,et al.Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance[J].Drug Resist Updat,2020(53):100715.
[6] FANG S,LIU M,LI L,et al.Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway[J].Oncogene,2019,38(21):4061-4074.
[7] HU Y B,YAN C,MU L,et al.Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance[J].Oncogene,2019,38(11):1951-1965.
[8] PEREKATT A O,SHAH P P,CHEUNG S,et al.SMAD4 suppresses WNT-driven dedifferentiation and oncogenesis in the differentiated gut epithelium[J].Cancer Res,2018,78(17):4878-4890.
[9] ZHANG Y,PAN Y,XIE C,et al.MiR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis[J].Cell Death Dis,2018,9(7):777.
[10] LE MAGNEN C,SHEN M M,ABATE-SHEN C.Lineage plasticity in cancer progression and treatment[J].Annu Rev Cancer Biol,2018(2):271-289.
[11] HAN H,WANG Y,CURTO J,et al.Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis[J].Cell Rep,2022,39(1):110595.
[12] IMAMURA J,GANGULY S,MUSKARA A,et al.Lineage plasticity and treatment resistance in prostate cancer:the intersection of genetics,epigenetics,and evolution[J].Front Endocrinol,2023(14):1191311.
[13] ISHAY-RONEN D,DIEPENBRUCK M,KALATHUR R K R,et al.Gain fat-lose metastasis:Converting invasive breast cancer cells into adipocytes inhibits cancer metastasis[J].Cancer Cell,2019,35(1):17-32.e6.
[14] MARJANOVIC N D,HOFREE M,CHAN J E,et al.Emergence of a high-plasticity cell state during lung cancer evolution[J].Cancer Cell,2020,38(2):229-246.e13.
[15] KONG F E,LI G M,TANG Y Q,et al.Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate[J].Sci Transl Med,2021,13(579):eabb6282.
[16] DOU C,LIU Z,TU K,et al.P300 acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts[J].Gastroenterology,2018,154(8):2209-2221.e14.
[17] WANG S,QU Y,XIA P,et al.Transdifferentiation of tumor infiltrating innate lymphoid cells during progression of colorectal cancer[J].Cell Res,2020,30(7):610-622.
[18] ZHAO C,GOMEZ G A,ZHAO Y,et al.ETV2 mediates endothelial transdifferentiation of glioblastoma[J].Signal Transduct Target Ther,2018(3):4.
[19] KRAH N M,NARAYANAN S M,YUGAWA D E.et al.PreventionYUGAWA D E.Prevention and reversion of pancreatic tumorigenesis through a differentiation-based mechanism[J].Dev Cell,2019,50(6):744-754.e4.
[20] BIEHS B,DIJKGRAAF G J P,PISKOL R,et al.A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition[J].Nature,2018,562(7727):429-433.
[21] GROVES S M,IRELAND A,LIU Q,et al.Cancer hallmarks define a continuum of plastic cell states between small cell lung cancer archetypes[M/OL].bioRxiv,2021:2021.01.22.427865[2024-01-04].https://www.biorxiv.org/content/10.1101/2021.01.22.427865v1.
[22] LAFAVE L M,KARTHA V K,MA S,et al.Epigenomic state transitions characterize tumor progression in mouse lung adenocarcinoma[J].Cancer Cell,2020,38(2):212-228.e13.
[23] FEDELE M,SGARRA R,BATTISTA S,et al.The epithelial-Mesenchymal transition at the crossroads between metabolism and tumor progression[J].Int J Mol Sci,2022,23(2):800.
[24] BAKIR B,CHIARELLA A M,PITARRESI J R,et al.EMT,MET,plasticity,and tumor metastasis[J].Trends Cell Biol,2020,30(10):764-776.
[25] KRÖGER C,AFEYAN A,MRAZ J,et al.Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells[J].Proc Natl Acad Sci USA,2019,116(15):7353-7362.
[26] ESPOSITO M,MONDAL N,GRECO T M,et al.Bone vascular niche E-selectin induces mesenchymal-epithelial transition and Wnt activation in cancer cells to promote bone metastasis[J].Nat Cell Biol,2019,21(5):627-639.
[27] DESHMUKH A P,VASAIKAR S V,TOMCZAK K,et al.Identification of EMT signaling cross-talk and gene regulatory networks by single-cell RNA sequencing[J].Proc Natl Acad Sci U S A,2021,118(19):e2102050118.
[28] JOLLY M K,MANI S A,LEVINE H.Hybrid epithelial/mesenchymal phenotype(s):The “fittest” for metastasis?[J].Biochim Biophys Acta Rev Cancer,2018,1870(2):151-157.
[29] LI Y,LV Z,ZHANG S,et al.Genetic fate mapping of transient cell fate reveals N-cadherin activity and function in tumor metastasis[J].Dev Cell,2020,54(5):593-607.e5.
[30] HANAHAN D.Hallmarks of cancer:New dimensions[J].Cancer Discov,2022,12(1):31-46.
[31] GAMEIRO P A,STRUHL K.Nutrient deprivation elicits a transcriptional and translational inflammatory response coupled to decreased protein synthesis[J].Cell Rep,2018,24(6):1415-1424.
[32] GUPTA P B,PASTUSHENKO I,et al.SKIBINSKI A.Phenotypic plasticity:Driver of cancer initiation,progression,and therapy resistance[J].Cell Stem Cell,2019,24(1):65-78.
[33] LAMBERT A W,WEINBERG R A.Linking EMT programmes to normal and neoplastic epithelial stem cells[J].Nat Rev Cancer,2021,21(5):325-338.
[34] LI L,ZENG Q,BHUTKAR A,et al.GKAP Acts as a Genetic Modulator of NMDAR Signaling to Govern Invasive Tumor Growth[J].Cancer Cell,2018,33(4):736-751.e5.
[35] WANG T,CHUFFART F,BOUROVA-FLIN E,et al.Histone variants:Critical determinants in tumour heterogeneity[J].Front Med,2019,13(3):289-297.
[36] CASTILHO R M,SQUARIZE C H,ALMEIDA L O.Epigenetic modifications and head and neck cancer:Implications for tumor progression and resistance to therapy[J].Int J Mol Sci,2017,18(7):1506.
[37] MU P,ZHANG Z,BENELLI M,et al.SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer[J].Science,2017,355(6320):84-88.
[38] KU S Y,ROSARIO S,WANG Y,et al.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity,metastasis,and antiandrogen resistance[J].Science,2017,355(6320):78-83.
[39] SINGH N,RAMNARINE V R,SONG J H,et al.The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer[J].Nat Commun,2021,12(1):7349.
[40] WINDER M,VIRÓS A.Mechanisms of drug resistance in melanoma[J].Handb Exp Pharmacol,2018(249):91-108.
[41] SHI Z D,PANG K,WU Z X,et al.Tumor cell plasticity in targeted therapy-induced resistance:Mechanisms and new strategies[J].Signal Transduct Target Ther,2023,8(1):113.
[42] 李桂霞,毕宇鑫,郝瑞家,等.靶向紧密连接蛋白6的药物在癌症治疗中的研究进展[J].生物工程学报,2023,39(4):1304-1313.
[43] WANG X,EICHHORN P J A,THIERY J P.TGF-β,EMT,and resistance to anti-cancer treatment[J].Semin Cancer Biol,2023(97):1-11.
[44] WATABE T,TAKAHASHI K,PIETRAS K,et al.Roles of TGF-β signals in tumor microenvironment via regulation of the formation and plasticity of vascular system[J].Semin Cancer Biol,2023(92):130-138.
[45] KATSUNO Y,DERYNCK R.Epithelial plasticity,epithelial-mesenchymal transition,and the TGF-β family[J].Dev Cell,2021,56(6):726-746.
[46] SINGH S,GOURI V,SAMANT M.TGF-β in correlation with tumor progression,immunosuppression and targeted therapy in colorectal cancer[J].Med Oncol,2023,40(11):335.
[47] KANG N,ECCLESTON M,CLERMONT P L,et al.EZH2 inhibition:A promising strategy to prevent cancer immune editing[J].Epigenomics,2020,12(16):1457-1476.
[48] EICH M L,ATHAR M,FERGUSON J E,et al.EZH2-targeted therapies in cancer:Hype or a reality[J].Cancer Res,2020,80(24):5449-5458.
[49] KIM H J,CANTOR H,COSMOPOULOS K.Overcoming immune checkpoint blockade resistance via EZH2 inhibition[J].Trends Immunol,2020,41(10):948-963.
[50] FOUSEK K,HORN L A,PALENA C.Interleukin-8:A chemokine at the intersection of cancer plasticity,angiogenesis,and immune suppression[J].Pharmacol Ther,2021(219):107692.
[51] DOS SANTOS A F,FAZELI G,XAVIER DA SILVA T N,et al.Ferroptosis:Mechanisms and implications for cancer development and therapy response[J].Trends Cell Biol,2023,33(12):1062-1076.
[52] LEE J,ROH J L.Epithelial-mesenchymal plasticity:Implications for ferroptosis vulnerability and cancer therapy[J].Crit Rev Oncol Hematol,2023(185):103964.

肿瘤可塑性与药物治疗抵抗

Tumor Plasticity and Therapeutic Resistance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价